SGFG
VERA icon

Silver Grove Financial Group’s Vera Therapeutics VERA Stock Holding History

Silver Grove Financial Group’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300 Buy
+7
New +$261 ﹤0.01% 2185

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Silver Grove Financial Group's VERA Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Vera Therapeutics (VERA) in Q2 2026: 7 shares worth $300. The stake represents ﹤0.01% of the portfolio and ranks #2185 among its holdings.

219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Silver Grove Financial Group held 7 shares of Vera Therapeutics worth $300 as of Q2 2026.
  • Vera Therapeutics was a new Silver Grove Financial Group position in Q2 2026.
  • Vera Therapeutics made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #2185 holding.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.